[Review: cimetidine: mode of action and clinical efficacy in various gastrointestinal diseases (author's transl)].
The development of the histamine-H2-receptor-antagonist cimetidine has led to a better understanding in the physiological control of gastric secretion and to a new approach in the management of various lesions of the upper gastrointestinal tract. Numerous world-wide controlled clinical trials have shown that the new drug is more efficient in diseases which are accompanied by hyperchlorhydria. This is especially true in the acute therapy and long-term prophylaxis of duodenal ulcer and in Zollinger-Ellison-syndrome. In contrast, at the present, the therapeutic benefit of cimetidine is less proven in gastric ulcer, in reflux oesophagitis and in acute hemorrhage of the upper gastrointestinal tract. Even under long-term administration no severe organic side effect occured with the drug which generally is well tolerated. Cimetidine appears as a valuable and safe agent, when the range of application is limited to defined gastrointestinal disorders.
D000208:Acute Disease; D002927:Cimetidine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy; D010188:Exocrine Pancreatic Insufficiency / Q000188:drug therapy; D005744:Gastric Acid / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy; D006146:Guanidines / Q000494:pharmacology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006801:Humans; D010195:Pancreatitis / Q000188:drug therapy; D010434:Pepsin A / Q000378:metabolism; D013276:Stomach Ulcer / Q000188:drug therapy; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D006146:Guanidines; D006634:Histamine H1 Antagonists; D002927:Cimetidine; D010434:Pepsin A
Ubersicht: Cimetidin Wirkungsweise und klinische Wirksamkeit bei verschiedenen gastrointestinalen Erkrankungen.